In 2025, Pharma Mar completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Pharma Mar has also provided a category-level breakdown for 8 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 1,296a | 1,340a | 1,233a | |
Total Scope 2 | ||||
Market-Based | 559a | 247a | 740a | |
Location-Based | 1,784a | 1,497a | 1,359a | |
Total Scope 3 | 13,581a | 16,132a | 15,876a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 4.9793a | 7.3644a | 7.0438a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Pharma Mar amounted to 3,080 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Pharma Mar increased by 8.57%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Pharma Mar were 1,296 metric tons of CO₂ equivalent (tCO₂e).a
Since 2021, Pharma Mar's Scope 1 emissions have decreased by 5.61%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2024), Pharma Mar's Scope 1 emissions decreased by 3.28%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2025, Pharma Mar reported Scope 2 greenhouse gas (GHG) emissions of 559 tCO₂e using the market-based method and 1,784 tCO₂e using the location-based method.a
Since 2021, Pharma Mar's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have increased by 41.7%, reflecting a rising long-term trend in Scope 2 emissions over time.a
Compared to the previous year (2024), Pharma Mar's Scope 2 emissions (Location-Based) rose by 19.17% in 2025, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2025, Pharma Mar reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2025, Pharma Mar reported 13,581 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Pharma Mar includes a breakdown across 8 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, Pharma Mar reported total Scope 3 emissions of 13,581 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2021, Pharma Mar's Scope 3 emissionshave remained relatively stable, indicating that Pharma Mar's emissions have plateaued with no significant change in its value chain footprint.a
Compared to the previous year (2024), Pharma Mar's Scope 3 emissions decreased by 15.81%, highlighting the company's efforts to lower indirect emissions from its value chain.a
In 2025, Pharma Mar reported emissions for 8 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
In 2025, the largest contributors to Pharma Mar's Scope 3 emissions were:a
In 2025, Pharma Mar reported Scope 1 greenhouse gas (GHG) emissions of 1,296 tCO₂e and total revenues of USD 260 millions. This translates into an emissions intensity of 4.98 tCO₂e per millions USD.a
In 2025, Pharma Mar reported a Scope 1 emissions intensity of 4.98 tCO₂e per millions USD. Compared to the peer group median of 3.89, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2025, Pharma Mar ranked 13 out of 22 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Pharma Mar is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2025, Pharma Mar reported a total carbon footprint of 16,661 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 12.17% decrease compared to 2024, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Pharma Mar's total carbon footprint was Scope 3 emissions, accounting for 81.51% of the company's total carbon footprint, followed by Scope 2 emissions at 10.71%.a